Sun Pharma launches Infugem in US market

Sun Pharma has declared the launch of Infugem which will be available commercially in the US. Infugem is the very first and only chemotherapy product available in a premixed and ready-to-infuse formulation. The shares of Sun Pharma opened in green on Monday.

The product was approved by the United States Food and Drug Association (USFDA) back in July 2018 coupled with some other drugs for the treatment of breast, ovarian, non-small cell lung cancer etc.

Infugem is an alcohol-free, clear, colourless, sterile solution of 10mg/mL gemcitabine in 0.9 per cent sodium chloride that is supplied to pharmacists in ready-to-infuse bags as a Spike & Go package. It is the only available gemcitabine formulation that does not require reconstitution and syringe withdrawal prior to intravenous administration. This property of the Infugem reduce complexity and minimizes the inherent risks of hazardous drug exposure, contamination, and medication errors.

On Monday, the shares of Sun Pharma opened at Rs. 469.90 against Friday’s close of Rs. 462.70. At 9:38 hours, the shares were trading at Rs. 464.40, up by 0.37 per cent. It reached an intraday high of Rs. 469.90 and an intraday low of Rs. 464 per share on the BSE. The 52-week high stood at Rs. 678.80 and 52-week low was at Rs. 375.40 per share on the BSE.

Meanwhile, the BSE Sensex was quoting 38,883.02, up by 0.02 per cent in the early session.